Omniab logo

Omniab Share Price (NASDAQ: OABI)

$1.89

0.09

(5%)

Live

Last updated on

Check the interactive Omniab Stock chart to analyse performance

Omniab stock performance

as on August 23, 2025 at 12:40 AM IST

  • Today's Low:$1.79
    Today's High:$1.89

    Day's Volatility :5.29%

  • 52 Weeks Low:$1.22
    52 Weeks High:$4.87

    52 Weeks Volatility :74.95%

Omniab Stock Returns

PeriodOmniab IncIndex (Russel 2000)
3 Months
30.07%
0.0%
6 Months
-50.82%
0.0%
1 Year
-55.9%
0.0%
3 Years
-25.52%
-7.7%

Omniab Inc Key Stats

Check Omniab key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.8
Open
$1.84
Today's High
$1.89
Today's Low
$1.79
Market Capitalization
$224.5M
Today's Volume
$654.9K
52 Week High
$4.87
52 Week Low
$1.22
Revenue TTM
$23.0M
EBITDA
$-51.3M
Earnings Per Share (EPS)
$-0.61
Profit Margin
-275.83%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-22.84%

Stock Returns calculator for Omniab Stock including INR - Dollar returns

The Omniab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Omniab investment value today

Current value as on today

₹50,692

Returns

₹49,308

(-49.31%)

Returns from Omniab Stock

₹53,563 (-53.56%)

Dollar Returns*

₹4,255 (+4.25%)

Indian investors sentiment towards Omniab Stock

-33%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Omniab Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Omniab Inc

  • Name

    Holdings %

  • BlackRock Inc

    5.75%

  • Vanguard Group Inc

    4.29%

  • Macquarie Group Ltd

    3.60%

  • Whitefort Capital Management, LP.

    3.19%

  • Dimensional Fund Advisors, Inc.

    2.37%

  • Rubric Capital Management LP

    2.32%

Analyst Recommendation on Omniab Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Omniab(by analysts ranked 0 to 5 stars)

Omniab Share Price Target

What analysts predicted

Upside of 315.72%

Target:

$7.86

Current:

$1.89

Omniab share price target is $7.86, a slight Upside of 315.72% compared to current price of $1.89 as per analysts' prediction.

Omniab Stock Insights

  • Price Movement

    In the last 7 days, OABI stock has moved down by -10.7%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 10.80M → 3.89M (in $), with an average decrease of 33.9% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -18.2M → -15.87M (in $), with an average increase of 14.7% per quarter
  • OABI vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 124.2%
  • Price to Sales

    ForOABI every $1 of sales, investors are willing to pay $8.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.6 for every $1 of sales.

Omniab Inc Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$26.4M
↓ 22.75%
Net Income
$-62.0M
↑ 22.55%
Net Profit Margin
-235.05%
↓ 86.89%

Omniab Technicals Summary

Sell

Neutral

Buy

Omniab is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Omniab Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Omniab Inc logo
-16.51%
-50.82%
-55.9%
-25.52%
-25.52%
Regeneron Pharmaceuticals, Inc. logo
4.5%
-14.59%
-49.64%
-0.73%
0.56%
Beone Medicines Ltd logo
6.48%
22.93%
60.47%
81.44%
32.24%
Vertex Pharmaceuticals Incorporated logo
-16.69%
-17.94%
-17.2%
38.81%
48.58%
Alnylam Pharmaceuticals, Inc. logo
43.34%
86.27%
68.31%
115.22%
254.29%

About Omniab Inc

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Organization
Omniab
Employees
114
CEO
Mr. Matthew W. Foehr
Industry
Healthcare

Key Management of Omniab Inc

NameTitle
Mr. Matthew W. Foehr
President, CEO & Director
Mr. Kurt A. Gustafson
Executive VP of Finance & CFO
Mr. Charles S. Berkman J.D.
Chief Legal Officer & Secretary
Ms. Cia McCaffrey
Vice President of People & Talent
Dr. Bill Harriman Ph.D.
Senior Vice President of Antibody Discovery
Dr. Christel Iffland Ph.D.
Senior Vice President of Antibody Technologies
Dr. Yasmina Noubia Abdiche Ph.D.
Senior Vice President of Exploratory Research
Ms. Donna Ventura CPA
Senior VP & Corporate Controller

Important FAQs about investing in OABI Stock from India :

What is Omniab share price today?

Omniab share price today is $1.89 as on . Omniab share today touched a day high of $1.89 and a low of $1.79.

What is the 52 week high and 52 week low for Omniab share?

Omniab share touched a 52 week high of $4.87 and a 52 week low of $1.22. Omniab stock price today i.e. is trending at $1.89, lower by 61.19% versus the 52 week high.

How to invest in Omniab Stock (OABI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Omniab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Omniab Shares that will get you 0.7937 shares as per Omniab share price of $1.89 per share as on August 23, 2025 at 12:40 AM IST.

What is the minimum amount required to buy Omniab Stock (OABI) from India?

Indian investors can start investing in Omniab (OABI) shares with as little as ₹87.499 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.99 in Omniab stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Omniab share’s latest price of $1.89 as on August 23, 2025 at 12:40 AM IST, you will get 5.2910 shares of Omniab. Learn more about fractional shares .

What are the returns that Omniab has given to Indian investors in the last 5 years?

Omniab stock has given -25.52% share price returns and 17.97% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?